Payers' Guide

FDA Approvals, Payers' Guide

Welcome to the Tenth Annual Payers’ Guide to New FDA Approvals

Select Drug Profiles, Payers' Guide

Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections

Select Drug Profiles, Payers' Guide

Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Olumiant (Baricitinib) Once-Daily Oral Drug Approved for the Treatment of Patients with Moderately to Severely Active Rheumatoid Arthritis

Select Drug Profiles, Payers' Guide

Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Select Drug Profiles, Payers' Guide

Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration

Lisa A. Raedler, PhD, RPh

Payers' Guide, Select Drug Profiles

Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura

Select Drug Profiles, Payers' Guide

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

1
2
3
4

Page 1 of 19
Results 1 - 10 of 185

SUBSCRIBE

Copyright © Amplity Medical Communications. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.